CHAMPIONS ONCOLOGY INC (CSBR) Fundamental Analysis & Valuation

NASDAQ:CSBR • US15870P3073

Current stock price

5.86 USD
-0.34 (-5.48%)
At close:
5.86 USD
0 (0%)
After Hours:

This CSBR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CSBR Profitability Analysis

1.1 Basic Checks

  • CSBR had negative earnings in the past year.
  • In the past year CSBR had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: CSBR reported negative net income in multiple years.
  • In multiple years CSBR reported negative operating cash flow during the last 5 years.
CSBR Yearly Net Income VS EBIT VS OCF VS FCFCSBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

  • CSBR has a better Return On Assets (8.26%) than 87.72% of its industry peers.
  • CSBR's Return On Equity of 59.76% is amongst the best of the industry. CSBR outperforms 98.25% of its industry peers.
  • The Return On Invested Capital of CSBR (24.26%) is better than 96.49% of its industry peers.
Industry RankSector Rank
ROA 8.26%
ROE 59.76%
ROIC 24.26%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSBR Yearly ROA, ROE, ROICCSBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • The Profit Margin of CSBR (4.27%) is better than 66.67% of its industry peers.
  • CSBR's Profit Margin has improved in the last couple of years.
  • CSBR's Operating Margin of 4.22% is in line compared to the rest of the industry. CSBR outperforms 59.65% of its industry peers.
  • CSBR's Operating Margin has improved in the last couple of years.
  • CSBR has a Gross Margin of 50.11%. This is comparable to the rest of the industry: CSBR outperforms 56.14% of its industry peers.
  • In the last couple of years the Gross Margin of CSBR has remained more or less at the same level.
Industry RankSector Rank
OM 4.22%
PM (TTM) 4.27%
GM 50.11%
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
CSBR Yearly Profit, Operating, Gross MarginsCSBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CSBR Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CSBR is creating value.
  • CSBR has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CSBR has more shares outstanding
  • The debt/assets ratio for CSBR is higher compared to a year ago.
CSBR Yearly Shares OutstandingCSBR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
CSBR Yearly Total Debt VS Total AssetsCSBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • CSBR has an Altman-Z score of 0.33. This is a bad value and indicates that CSBR is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.33, CSBR is doing worse than 66.67% of the companies in the same industry.
  • CSBR has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
  • CSBR has a better Debt to FCF ratio (0.03) than 94.74% of its industry peers.
  • CSBR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • CSBR's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. CSBR outperforms 68.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 0.33
ROIC/WACC2.21
WACC10.99%
CSBR Yearly LT Debt VS Equity VS FCFCSBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 0.96 indicates that CSBR may have some problems paying its short term obligations.
  • The Current ratio of CSBR (0.96) is worse than 91.23% of its industry peers.
  • CSBR has a Quick Ratio of 0.96. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.96, CSBR is doing worse than 85.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.96
CSBR Yearly Current Assets VS Current LiabilitesCSBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CSBR Growth Analysis

3.1 Past

  • CSBR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -109.43%.
  • CSBR shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 146.62% yearly.
  • CSBR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.54%.
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)-109.43%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-105.56%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-2.81%

3.2 Future

  • The Earnings Per Share is expected to decrease by -52.39% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 18.26% on average over the next years. This is quite good.
EPS Next Y-72.8%
EPS Next 2Y-52.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.41%
Revenue Next 2Y7.38%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CSBR Yearly Revenue VS EstimatesCSBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
CSBR Yearly EPS VS EstimatesCSBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

3

4. CSBR Valuation Analysis

4.1 Price/Earnings Ratio

  • CSBR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • CSBR is valuated quite expensively with a Price/Forward Earnings ratio of 57.45.
  • CSBR's Price/Forward Earnings is on the same level as the industry average.
  • When comparing the Price/Forward Earnings ratio of CSBR to the average of the S&P500 Index (23.28), we can say CSBR is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 57.45
CSBR Price Earnings VS Forward Price EarningsCSBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • CSBR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CSBR is cheaper than 75.44% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CSBR is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.43
EV/EBITDA 18.39
CSBR Per share dataCSBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • CSBR has a very decent profitability rating, which may justify a higher PE ratio.
  • CSBR's earnings are expected to decrease with -52.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.39%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CSBR Dividend Analysis

5.1 Amount

  • CSBR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CSBR Fundamentals: All Metrics, Ratios and Statistics

CHAMPIONS ONCOLOGY INC

NASDAQ:CSBR (3/20/2026, 8:00:01 PM)

After market: 5.86 0 (0%)

5.86

-0.34 (-5.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-12
Earnings (Next)07-21
Inst Owners47.9%
Inst Owner Change1.53%
Ins Owners26.55%
Ins Owner Change0%
Market Cap81.40M
Revenue(TTM)56.94M
Net Income(TTM)2.49M
Analysts82.86
Price Target12.24 (108.87%)
Short Float %0.68%
Short Ratio11.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)196.08%
Min EPS beat(2)96.08%
Max EPS beat(2)296.08%
EPS beat(4)4
Avg EPS beat(4)1021.81%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)7
Avg EPS beat(8)610.2%
EPS beat(12)8
Avg EPS beat(12)364.99%
EPS beat(16)10
Avg EPS beat(16)253.89%
Revenue beat(2)2
Avg Revenue beat(2)3.27%
Min Revenue beat(2)1.54%
Max Revenue beat(2)5.01%
Revenue beat(4)4
Avg Revenue beat(4)9.14%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)7
Avg Revenue beat(8)4.71%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)10
Avg Revenue beat(16)1.37%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-45.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 57.45
P/S 1.39
P/FCF 14.43
P/OCF 13.08
P/B 19.52
P/tB 21.22
EV/EBITDA 18.39
EPS(TTM)-0.05
EYN/A
EPS(NY)0.1
Fwd EY1.74%
FCF(TTM)0.41
FCFY6.93%
OCF(TTM)0.45
OCFY7.65%
SpS4.21
BVpS0.3
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.26%
ROE 59.76%
ROCE 30.71%
ROIC 24.26%
ROICexc N/A
ROICexgc N/A
OM 4.22%
PM (TTM) 4.27%
GM 50.11%
FCFM 9.65%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score7
Asset Turnover1.94
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.01
Cap/Depr 38.69%
Cap/Sales 1%
Interest Coverage 250
Cash Conversion 156.75%
Profit Quality 226.32%
Current Ratio 0.96
Quick Ratio 0.96
Altman-Z 0.33
F-Score7
WACC10.99%
ROIC/WACC2.21
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-109.43%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-105.56%
EPS Next Y-72.8%
EPS Next 2Y-52.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.54%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-2.81%
Revenue Next Year3.41%
Revenue Next 2Y7.38%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y799.72%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-50.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y216.22%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y346.75%
OCF growth 3Y4.35%
OCF growth 5Y20.48%

CHAMPIONS ONCOLOGY INC / CSBR Fundamental Analysis FAQ

What is the fundamental rating for CSBR stock?

ChartMill assigns a fundamental rating of 4 / 10 to CSBR.


Can you provide the valuation status for CHAMPIONS ONCOLOGY INC?

ChartMill assigns a valuation rating of 3 / 10 to CHAMPIONS ONCOLOGY INC (CSBR). This can be considered as Overvalued.


Can you provide the profitability details for CHAMPIONS ONCOLOGY INC?

CHAMPIONS ONCOLOGY INC (CSBR) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for CSBR stock?

The Earnings per Share (EPS) of CHAMPIONS ONCOLOGY INC (CSBR) is expected to decline by -72.8% in the next year.